AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29788348 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or no vaccine)
Number of subjects: 0
Study 29788349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine against Ebola
Number of subjects: 0
Study 29788349 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29788444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower urinary norepinephrine
Number of subjects: 12
Study 29788444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower free T4
Number of subjects: 12
Study 29788444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower CIBA
Number of subjects: 12
Study 29788444 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher urinary norepinephrine
Number of subjects: 12
Study 29788444 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher free T4
Number of subjects: 12
Study 29788497 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2256098 (1000 mg, 750 mg, 500 mg; dosed twice daily)
Number of subjects: 13
Study 29788497 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2256098 (PET substudy)
Number of subjects: 13
Study 29788497 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2256098
Number of subjects: 13
Study 29788694 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily for first 3 weeks, followed by 20 mg once daily for 6 months
Number of subjects: 124
Study 29788910 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound infection (verified by positive culture)
Number of subjects: 457
Study 29788919 — intervention group
Group type: EXPERIMENTAL
Intervention: PiCCOplus (SVV)
Number of subjects: 30
Study 29788919 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional hemodynamic parameters (except for PVI)
Number of subjects: 30
Study 29788919 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI
Number of subjects: 30
Study 29788942 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell (BMC) implantation
Number of subjects: 33
Study 29788998 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report depression screening tool (9-item Patient Health Questionnaire - PHQ-9)
Number of subjects: 319
Study 29788998 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally adapted stigma measures
Number of subjects: 319
Study 29789017 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT worksheets completed on paper forms
Number of subjects: 0
Study 29789017 — intervention group
Group type: COMPARATOR
Intervention: CBT worksheets completed on a mobile application (app)
Number of subjects: 0
Study 29789029 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural neuroimaging studies in Down syndrome (DS)
Number of subjects: 0
Study 29789029 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical lobar effect sizes from early childhood through adolescence
Number of subjects: 0
Study 29789029 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal GM volume in Down syndrome
Number of subjects: 0
Study 29789238 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-TDV administered by PharmaJet
Number of subjects: 67
Study 29789238 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous injection of two LD-TDV doses
Number of subjects: 67
Study 29789238 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-TDV (one or two doses)
Number of subjects: 67
Study 29789238 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-TDV (two doses given either concomitantly or 90 days apart)
Number of subjects: 67
Study 29789238 — intervention group
Group type: EXPERIMENTAL
Intervention: LD-TDV (overall safety assessment)
Number of subjects: 67
Study 29789277 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based perioperative exercise program (iPEP study)
Number of subjects: 20
Study 29789277 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for hepatic inflammation and physical performance (HELP study)
Number of subjects: 20
Study 29789277 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based exercise for depression (EXDEP study)
Number of subjects: 20
Study 29789277 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based mentoring for microbiome, exercise, and diet (COMMED study)
Number of subjects: 20
Study 29789395 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP <140 mm Hg achieved within 2 hours (reduced and maintained)
Number of subjects: 1000
Study 29789395 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP <140 mm Hg achieved within 2 hours (reduced but not maintained)
Number of subjects: 1000
Study 29789395 — intervention group
Group type: COMPARATOR
Intervention: Subjects without reduction of SBP <140 mm Hg within 2 hours
Number of subjects: 1000
Study 29789639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine as part of the lymphodepleting chemotherapy regimen prior to ACT
Number of subjects: 0
Study 29789639 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine in the preconditioning regimen
Number of subjects: 0
Study 29789971 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program
Number of subjects: 168
Study 29789971 — intervention group
Group type: EXPERIMENTAL
Intervention: Restriction of intravenous fluid element
Number of subjects: 168
Study 29789971 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during the early study period
Number of subjects: 168
Study 29789971 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 168
Study 29789971 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative morbidity
Number of subjects: 168
Study 29790103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (30, 50 or 70 mg/day)
Number of subjects: 314
Study 29790125 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic interventions for the management of bleeding (fluid replacement, red blood cells transfusion, prothrombin complex concentrates, antifibrinolytic drugs, idarucizumab)
Number of subjects: 117
Study 29790125 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of bleeding patients
Number of subjects: 117
Study 29790125 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of bleeding complications in patients treated with DOACs
Number of subjects: 117
Study 29792074 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinnitus Retraining Therapy (TRT) including tinnitus-specific educational counseling and sound therapy
Number of subjects: 0
Study 29792074 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 29792535 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (PARP inhibitor) combined with topotecan
Number of subjects: 60
Study 29792726 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxious youth
Number of subjects: 31
Study 29792726 — intervention group
Group type: COMPARATOR
Intervention: Healthy youth
Number of subjects: 31
Study 29793397 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS (smartphone-delivered intervention)
Number of subjects: 163
Study 29793397 — intervention group
Group type: COMPARATOR
Intervention: WRAP (clinic-based group intervention)
Number of subjects: 163
Study 29793397 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUS
Number of subjects: 163
Study 29793397 — intervention group
Group type: COMPARATOR
Intervention: WRAP
Number of subjects: 163
Study 29793397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 163
Study 29793553 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School Mental Health Manual-based intervention in three 6-h, face-to-face sessions
Number of subjects: 0
Study 29793553 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (not receiving training during the study period)
Number of subjects: 0
Study 29793553 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School Mental Health Manual-based intervention
Number of subjects: 0
Study 29793587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 4 g dose administered before surgery
Number of subjects: 116
Study 29793590 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical autopsy and virtual autopsy (Group M/V)
Number of subjects: 162
Study 29793590 — intervention group
Group type: COMPARATOR
Intervention: Virtual autopsy only (Group V)
Number of subjects: 162
Study 29793590 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and virtual autopsy (Group M/V)
Number of subjects: 162
Study 29793604 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 20
Study 29794066 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day and octreotide 30 mg every 28 days
Number of subjects: 43
Study 29794089 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional treatment
Number of subjects: 1500
Study 29794089 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniotomy
Number of subjects: 1500
Study 29794089 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional therapy
Number of subjects: 1500
Study 29794089 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniotomy clipping
Number of subjects: 1500
Study 29794089 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional treatment and Craniotomy
Number of subjects: 1500
Study 29794101 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic thrombolysis, endovascular treatment or both
Number of subjects: 140
Study 29795625 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 4549
Study 29795625 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia during pregnancy
Number of subjects: 4549
Study 29795625 — intervention group
Group type: EXPERIMENTAL
Intervention: Gonorrhea during pregnancy
Number of subjects: 4549
Study 29795625 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichomoniasis during pregnancy
Number of subjects: 4549
Study 29795625 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV during pregnancy
Number of subjects: 4549
Study 29795625 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall STI incidence during pregnancy
Number of subjects: 4549
Study 29796289 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Number of subjects: 0
Study 29796622 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU or 2000 IU vitamin D3/d
Number of subjects: 78
Study 29796622 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplement intake >872 IU/d
Number of subjects: 78
Study 29796622 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age and 25(OH)D concentration
Number of subjects: 78
Study 29796622 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D concentration <13 ng/mL
Number of subjects: 78
Study 29796622 — intervention group
Group type: COMPARATOR
Intervention: Standard prenatal supplementation
Number of subjects: 78
Study 29796622 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean serum 1,25(OH)2D
Number of subjects: 78
Study 29796648 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Exercise Training (RET) for 12 weeks (60-75% 1-repetition maximum)
Number of subjects: 19
Study 29796648 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential Amino Acids (EAA) ingestion (6.8 g)
Number of subjects: 19
Study 29796648 — intervention group
Group type: EXPERIMENTAL
Intervention: RET
Number of subjects: 19
Study 29796652 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocephalus or contrast-enhancing ventricles
Number of subjects: 71
Study 29796652 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenchymal images (abscesses, nodules, or white matter images)
Number of subjects: 71
Study 29796652 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenchymal images
Number of subjects: 71
Study 29796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturia involving ≥ 2 nocturnal voids
Number of subjects: 8284
Study 29796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbid conditions and lower urinary tract symptoms (LUTS)
Number of subjects: 8284
Study 29796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex, age > 60 years, diabetes, cardiac disease, body mass index, IPSS voiding score, stress urinary incontinence, wet OAB, HADS anxiety score
Number of subjects: 8284
Study 29796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 8284
Study 29796775 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 8284
Study 29797054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabry-specific stroke risk score
Number of subjects: 159
Study 29797054 — intervention group
Group type: COMPARATOR
Intervention: CHA score
Number of subjects: 159
Study 29797069 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative computed tomography (QCT) imaging measurement of airway wall thickness (WAP)
Number of subjects: 799
Study 29797069 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodic spirometries
Number of subjects: 799
Study 29797069 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 799
Study 29797559 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepEE
Number of subjects: 72
Study 29797559 — intervention group
Group type: EXPERIMENTAL
Intervention: TDEE
Number of subjects: 72
Study 29797583 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCOS-102 (AdV5/3-D24-GM-CSF)
Number of subjects: 0
Study 29797706 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR performed by EMS according to European Resuscitation Council Resuscitation Guidelines (2010)
Number of subjects: 149
Study 29797706 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-related injuries
Number of subjects: 149
Study 29797706 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age, male gender, and public location
Number of subjects: 149
Study 29797706 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of CPR attempts
Number of subjects: 149
Study 29797710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative sepsis
Number of subjects: 1894
Study 29797710 — intervention group
Group type: COMPARATOR
Intervention: No pre-operative sepsis
Number of subjects: 1894
Study 29798770 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-coated balloon treatment
Number of subjects: 1406
Study 29798831 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based transdiagnostic intervention (10 weeks, based on the Unified Protocol for Transdiagnostic Treatment of Emotional Disorders)
Number of subjects: 105
Study 29798831 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based transdiagnostic intervention
Number of subjects: 105
Study 29798831 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 105
Study 29799100 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous semaglutide (1.5 mg supratherapeutic dose)
Number of subjects: 168
Study 29799100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 29799329 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 0
Study 29799545 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine 0.5 g/kg/day
Number of subjects: 2700
Study 29799545 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric maltodextran control
Number of subjects: 2700
Study 29799874 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating complement-activating anti-HLA DSAs
Number of subjects: 7936
Study 29799915 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol eyedrops
Number of subjects: 0
Study 29799915 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or alternative treatment not specified)
Number of subjects: 0
Study 29800033 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway transplantation using human cryopreserved aortic allograft with custom-made stent
Number of subjects: 20
Study 29800033 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway transplantation
Number of subjects: 20
Study 29800181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity imaging surveillance (mean of 2.9 scans)
Number of subjects: 8529
Study 29800181 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity imaging surveillance (mean of 1.6 scans)
Number of subjects: 8529
Study 29800181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity CEA testing (mean of 4.3 tests)
Number of subjects: 8529
Study 29800181 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity CEA testing (mean of 1.6 tests)
Number of subjects: 8529
Study 29800181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity imaging surveillance
Number of subjects: 8529
Study 29800181 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity imaging surveillance
Number of subjects: 8529
Study 29800181 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity CEA testing
Number of subjects: 8529
Study 29800181 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity CEA testing
Number of subjects: 8529
Study 29800309 — intervention group
Group type: EXPERIMENTAL
Intervention: Live zoster VZVOka vaccine
Number of subjects: 44
Study 29800971 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (fluorouracil, irinotecan, and oxaliplatin) for 8 cycles followed by individualized chemoradiotherapy (5 Gy × 5 with protons) with capecitabine for patients with resolution of vascular involvement; long-course chemoradiotherapy with fluorouracil or capecitabine for patients with persistent vascular involvement.
Number of subjects: 48
Study 29801465 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib at 150 mg/day
Number of subjects: 62
Study 29801483 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass-treatment with praziquantel tablets as part of a Department of Health Mass-Treatment Campaign for schistosomiasis.
Number of subjects: 6
Study 29801483 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Group Discussions and individual in-depth interviews to assess barriers to treatment.
Number of subjects: 6
Study 29801516 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with delirium
Number of subjects: 50
Study 29801516 — intervention group
Group type: COMPARATOR
Intervention: Patients without delirium
Number of subjects: 50
Study 29801520 — intervention group
Group type: EXPERIMENTAL
Intervention: G + A intervention (gambling intervention combined with problem drinking intervention)
Number of subjects: 280
Study 29801520 — intervention group
Group type: COMPARATOR
Intervention: G-only intervention (targets only gambling issues)
Number of subjects: 280
Study 29802016 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive FSS derived from coronary computed tomography angiography (CTA)
Number of subjects: 77
Study 29802016 — intervention group
Group type: COMPARATOR
Intervention: Anatomic SYNTAX score (SS) calculated by CTA
Number of subjects: 77
Study 29802016 — intervention group
Group type: COMPARATOR
Intervention: Invasive FSS
Number of subjects: 77
Study 29802041 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCLUDER device in narrow AOB cohort (NB)
Number of subjects: 1055
Study 29802041 — intervention group
Group type: COMPARATOR
Intervention: EXCLUDER device in standard bifurcation cohort (SB)
Number of subjects: 1055
Study 29802041 — intervention group
Group type: EXPERIMENTAL
Intervention: EXCLUDER device in both cohorts
Number of subjects: 1055
Study 29802077 — intervention group
Group type: EXPERIMENTAL
Intervention: Free omega-3 fatty acids
Number of subjects: 315
Study 29802077 — intervention group
Group type: COMPARATOR
Intervention: Esterified omega-3 fatty acids
Number of subjects: 315
Study 29802077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low FE-1 levels
Number of subjects: 315
Study 29802091 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed cognitive behavioral therapy (CBT), eight-session antenatal intervention.
Number of subjects: 20
Study 29802091 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of women who did not receive perinatal CBT).
Number of subjects: 20
Study 29802148 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher densities of fast-food restaurants (FFRs)
Number of subjects: 0
Study 29802148 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-service restaurants
Number of subjects: 0
Study 29802148 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly defined
Number of subjects: 0
Study 29802538 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 45
Study 29802538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29802551 — intervention group
Group type: EXPERIMENTAL
Intervention: Amrubicin 40-80 mg/m² intravenously combined with lenalidomide and weekly dexamethasone
Number of subjects: 0
Study 29802636 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus therapy
Number of subjects: 236
Study 29802636 — intervention group
Group type: COMPARATOR
Intervention: Basal insulin-only therapy
Number of subjects: 236
Study 29802952 — intervention group
Group type: EXPERIMENTAL
Intervention: DDS-2
Number of subjects: 338
Study 29802952 — intervention group
Group type: EXPERIMENTAL
Intervention: PAID-5
Number of subjects: 338
Study 29803683 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncylindrical neck patients
Number of subjects: 3077
Study 29803683 — intervention group
Group type: COMPARATOR
Intervention: Cylindrical neck patients
Number of subjects: 3077
Study 29803683 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 3077
Study 29803683 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck shape morphology
Number of subjects: 3077
Study 29803683 — intervention group
Group type: EXPERIMENTAL
Intervention: AAA diameter
Number of subjects: 3077
Study 29803695 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiology assessment group (n=1,177)
Number of subjects: 1858
Study 29803695 — intervention group
Group type: COMPARATOR
Intervention: Visual estimation group (n=681)
Number of subjects: 1858
Study 29803695 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall use of physiology guidance
Number of subjects: 1858
Study 29803987 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery function-guided diagnosis and treatment
Number of subjects: 0
Study 29803987 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 0
Study 29804060 — intervention group
Group type: EXPERIMENTAL
Intervention: Present screening with liquid-based cytology every third year (present programme arm)
Number of subjects: 0